Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER.
CEFMAX vs CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
1-2 g IV every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic